Antimüllerian Hormone Association with Polycystic Ovary Syndrome and Pregnancy Outcomes of in Vitro Fertilization Cycles with Fresh Embryo Transfer

Background & Objective: Predicting ovarian response using patient features and biomarkers is crucial for optimizing and individualizing controlled ovarian hyperstimulation (COH) for in vitro fertilization (IVF). Member of the transforming growth factor- superfamily; also known as antimüllerian hormone (AMH) or müllerian inhibitory substance. The research examines the relationship between antimüllerian hormone and Polycystic Ovarian Syndrome (PCOS) and in vitro fertilization cycles with fresh embryo transfer.Materials & Methods: Cross-sectional study of ۵۵ infertile females with PCOS undergoing in vitro fertilization cycles in Baghdad and Al-Najaf infertility centers from June ۲۰۲۲ to June ۲۰۲۳. All female data are: Age groups (years), AMH level Ng/ml, Infertility period (years), Male variables, Outcome (pregnancy test), and Infertility causes.Results: In vitro fertilization cycles in ۵۵ infertile women with PCOs. Mean age of females (۳۰ ± ۶ years), ۷۸.۲% less than ۳۵ years old, ۳۸.۲% fertility period ۲–۵ years, ۳۰.۹% male infertility, ۲۹.۱% pregnancy, ۷۲.۷% AMH ۲۰۲۵-۵.۷۱ ng/ml. ۸۰% of women have no infertility issues, ۷.۲۷% have tubal obstruction, ۳.۶۴% have had Cesarean section (CS), etc. ۱۰۰% of females under ۳۵ have AMH (۲.۲۵-۵.۷۱ ng/ml). AMH does not significantly affect (Infertility Period, Outcome, and Protocol Used).Conclusion: The study highlights AMH as an indicator of ovarian reserve decline in females aged ≥ ۳۵ years, while emphasizing the multifaceted determinants of infertility and IVF success.

کلیدواژه ها:

Antimüllerian ، Polycystic Ovary Syndrome ، Pregnancy Outcomes ، In vitro fertilization